Autolus Therapeutics (AUTL) reported third-quarter 2026 net product revenue of $41.2 million, up 95% from $21.1 million a year earlier. Total revenue was $41.238 million, while net loss narrowed to $55.1 million from $79.1 million.
The company raised its outlook, saying full-year 2026 AUCATZYL net product revenue is expected to reach or exceed the upper end of $150 million. Cash, cash equivalents and marketable securities totaled $248.4 million at September 30, 2026.
- Basic and diluted net loss per ordinary share was $0.21, compared with $0.30 a year earlier.
- Third-quarter gross margin was 57%, compared with 55% in the second quarter of 2026.
- Research and development expense was $30.9 million; selling, general and administrative expense was $35.9 million.
- Autolus expects its cash resources, including anticipated credit-facility proceeds, to fund operations into the second quarter of 2028.
- The company said pediatric ALL, lupus nephritis and progressive multiple sclerosis studies remain ongoing.
$AUTL Insider Trading Activity
$AUTL insiders have traded $AUTL stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $AUTL stock by insiders over the last 6 months:
- CINTIA PICCINA (U.S. CCO & Country Gen Manager) sold 6,713 shares for an estimated $15,681
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AUTL Hedge Fund Activity
We have seen 39 institutional investors add shares of $AUTL stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 1,656,063 shares (-17.5%) from their portfolio in Q2 2026, for an estimated $2,649,700
- MILLENNIUM MANAGEMENT LLC added 1,020,090 shares (+498.3%) to their portfolio in Q2 2026, for an estimated $1,632,144
- JPMORGAN CHASE & CO added 913,239 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,461,182
- ARMISTICE CAPITAL, LLC removed 800,000 shares (-5.1%) from their portfolio in Q2 2026, for an estimated $1,280,000
- ALPHABET INC. removed 698,262 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $1,354,628
- POINT72 ASSET MANAGEMENT, L.P. removed 355,756 shares (-83.3%) from their portfolio in Q2 2026, for an estimated $569,209
- MORGAN STANLEY added 319,009 shares (+33.9%) to their portfolio in Q2 2026, for an estimated $510,414
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.